Results 191 to 200 of about 6,418,846 (364)

GRANULOSA CELL TUMOR OF THE OVARY

, 1940
Prank L. Barnes, J. Peyton Barnes
openalex   +2 more sources

Ein unter dem Bilde der multiplen Sklerose verlaufender intramedullärer Tumor spinalis [PDF]

, 1921
Hans Heinrich Müller, Bernhard Dattner
openalex   +1 more source

Outer membrane vesicles-based nano-regulator for cancer immunotherapy by modulating neutrophils N1 polarization and hitchhiking delivery. [PDF]

J Nanobiotechnology
Liu X, Niu Q, Yang H, Du T, Liu Y, Zhou H, Wang S, Shen L, Wang X, Zhang G, He H.   +10 more
europepmc   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

The Uptake of Lipoproteins by Ascites Tumor Cells

, 1958
Dorothy L. Fillerup, Joseph C. Migliore, James F. Mead   +2 more
openalex   +1 more source

Investigations of a Factor Found in Certain Normal Tissues Inhibiting Ascites Tumor Growth in the Rat and Mouse [PDF]

, 1959
Elke Hartmann
openalex   +1 more source

B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors. [PDF]

Cancer Metastasis Rev
Jansen L, Wienke J, Molkenbur R, Rossig C, Meissner R.   +4 more
europepmc   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

FURTHER INVESTIGATIONS ON THE ORIGIN OF TUMORS IN MICE [PDF]

, 1918
A. E. C. Lathrop, Leo Loeb
openalex   +1 more source

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

New England Journal of Medicine, 2004
M. Cristofanilli, G. Budd, M. Ellis, A. Stopeck, J. Matera, M. Miller, J. Reuben, G. Doyle, W. Allard, L. Terstappen, D. Hayes   +10 more
semanticscholar   +1 more source